Investor FAQs

 

The Tobira Therapeutics is traded on the NASDAQ under the symbol “TBRA” 

Tobira Therapeutics became a public company effective May 04, 2015 resulting from a reverse merger with Regado Biosciences. Regado Biosciences became a publicly traded company on August 22, 2013 through an initial public offering (IPO).

Corporate Headquarters
701 Gateway Blvd, Suite 300
South San Francisco, CA   94080

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

You can view our management team by visiting the Management section of our Investor Relations website.

Our fiscal year ends on December 31st

Ernst & Young LLP
275 Shoreline Drive, Suite 600
Redwood City, CA  94065

Tobira Therapeutics does not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations in our business. 

Tobira Therapeutics does not currently offer a direct stock purchase plan.

Quarterly & Annual reports and other investor materials are available under “Financial Information” of the “Investors” section of our corporate website.  Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.

You can contact Tobira Therapeutics Investor Relations via email at: ir@tobiratx.com

Please submit your question using the form below.

* Indicates required field